Ilanit Itzhaki

TL;DR: The ability of human iPSC technology to model the abnormal functional phenotype of an inherited cardiac disorder and to identify potential new therapeutic agents represents a promising paradigm to study disease mechanisms, optimize patient care, and aid in the development of new therapies.

TL;DR: HES‐CMs at mid‐range development express prominent Na+ current, and the absence of background K+ current creates conditions for spontaneous activity that is sensitive to TTX in the same range of partial block of NaV1.5; thus, the NaV 1.5 Na+ channel is important for initiating spontaneous excitability in hES‐derived heart cells.

TL;DR: The generation of stable transgenic hESC lines may be used to identify and study early cardiac precursors for developmental studies, to robustly quantify the extent of cardiomyocyte differentiation, to label the cells for in vivo grafting, and to allow derivation of purified cell populations ofCardiomyocytes for future myocardial cell therapy strategies.

TL;DR: It is hypothesized that human embryonic stem cell-derived cardiomyocytes assessed with a combination of single cell electrophysiology and microelectrode array (MEA) mapping can serve as a novel model for Electrophysiological drug screening.

TL;DR: This study highlights the potential of hiPSCs for studying inherited arrhythmogenic syndromes, in general, and CPVT specifically and represents a promising paradigm to study disease mechanisms, optimize patient care, and aid in the development of new therapies.